# IXO+A in mCRC With Liver-only Metastases

> **NCT01293942** · PHASE2 · WITHDRAWN · sponsor: **Ottawa Hospital Research Institute**

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab

## Key facts

- **NCT ID:** NCT01293942
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01293942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01293942, "IXO+A in mCRC With Liver-only Metastases". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01293942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*